Upcoming webinar

My patient is Signatera™-positive. Now what?

Translating MRD detection into action

Date: Friday, June 26, 2026
Time: 12:00 PM PT | 3:00 PM ET
Webinar duration: 30 minutes
Registrants will receive a recording of the webinar approximately one week after the event.
As molecular residual disease (MRD) testing becomes increasingly integrated into oncology practice, clinicians are tackling important questions around interpretation, treatment planning, and patient communication following ctDNA positivity.

This webinar will provide a practical framework for managing patients with a positive Signatera™ result across multiple cancer types and settings including:

  • How ctDNA positivity can inform surveillance strategies, multidisciplinary discussions, clinical trial enrollment and therapeutic considerations in a real-world practice
  • The correlation between MRD positivity, recurrence risk and importance of tracking ctDNA trends over time through longitudinal monitoring
  • Viewers will come away with practical approaches for interpreting positive MRD results and navigating the vital role of ctDNA centered around patient quality of life.

Register Now:

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:


Noam Drazin, MD
Noam Drazin, MD
Hematologist/Oncologist
Cedars Sinai Cancer
Kevin Manage, PhD
Kevin Manage, PhD
Oncology MSL Manager
Natera
Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy